Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

RFK Jr. is declaring war on chronic illness, which, if he succeeds, will not only make us healthier but will also cut down ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Vizient, Inc. released its new Spend Management Outlook representing the best estimate of the change in the price of pharmaceuticals, medical devices and supplies, capital equipment and services ...

The Kokomo woman was pre-diabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Eli Lilly's weight-loss jab Mounjaro has been cleared for rollout by the NHS in England, with around 3.4 million people eligible, but will be made available in stages to limit the financial impact.